Memorandum of Understanding Between the Health Information Sharing & Analysis Center, Inc. (H-ISAC), Sensato Critical Infrastructure ISAO (Sensato-ISAO) and the U.S. Food and Drug Administration Center For Devices and Radiological Health

I. Purpose

The United States Food and Drug Administration (FDA)'s Center for Devices and Radiological Health (CDRH) and the Health Information Sharing & Analysis Center, Inc. (H-ISAC), formerly known as the National Health Information Sharing & Analysis Center, Inc. (NH-ISAC), and Sensato Critical Infrastructure ISAO have a shared interest in encouraging the identification, mitigation, and prevention of cybersecurity threats to medical devices.   FDA, H-ISAC and Sensato-ISAO are each referred to individually as a "Party" and collectively as the "Parties." This Memorandum of Understanding (MOU) establishes the terms for collaboration to promote this shared interest.

II. Background

1. FDA is authorized to enforce the Federal Food, Drug,and Cosmetic Act ("the Act") as amended (21 U.S.C. 301). In fulfilling its responsibilities under the Act, FDA among other things, directs its activities toward promoting and protecting the public health by ensuring the safety, efficacy, and security of drugs, biological products, veterinary products, medical devices and radiological products and the safety and security of foods and cosmetics. CDRH is responsible for assuring that patients and providers have timely and continued access to safe, effective, and high-quality medical devices and safe radiation-emitting products. To accomplish its mission, FDA takes efforts to stay abreast of the latest technological advances and developments in research by communicating with stakeholders about complex scientific and public health issues.

2. H-ISAC, a member owned non-profit organization, is the Information Sharing and Analysis Center (ISAC) for the nation's healthcare and public health critical infrastructure, recognized by the U.S. Department of Health and Human Services (HHS), the HHS Health Sector Coordinating Council (SCC), the US Department of Homeland Security (OHS), the National Council of ISACs (representing all the nation's critical infrastructures ISACs), intelligence agencies, law enforcement and the health sector.

H-ISAC is a member-driven system of security intelligence information exchange among trusted entities for the purposes of providing members with actionable cybersecurity for intelligence situational awareness, information sharing capabilities supporting effective countermeasure solutions, and coordinated cybersecurity incident response. As a non­ profit organization, H-ISAC represents a trusted community comprised of national healthcare and public health critical infrastructure owners and operators and the organizations supporting the health sector.

The mission of the H-ISAC is to foster, enable and preserve the public trust by advancing health sector physical and cybersecurity resilience and the ability to prepare for and respond to threats and vulnerabilities.

3. Sensato-ISAO, owned and operated by Sensato Cybersecurity Solutions, is an Information Sharing and Analysis Organization that focuses on the sharing of cybersecurity threat intelligence, best practices, toolkits and other assets across its member base and with vetted and interested parties and organizations across the United States.

The Sensato-ISAO embraces a community model that is relies on tactical principles and strategies in order to provide a rapid response capability to its members, partners and other interested and vetted parties. The Sensato-ISAO is designed to eventually provide cross sector intelligence, practices and assets among the sixteen critical infrastructure sectors as defined by U.S. Department of Homeland Security. This includes the integration and fusion of intelligence and other information that directly impacts the healthcare sector and most specifically those threats which could be an impact to patient safety.

4. Executive Order 13636 articulates that cyber threats continue to grow and are one of the most serious threats to national security. Furthermore, Presidential Policy Directive 21tasks federal government entities with the responsibility to strengthen the security and resilience of critical infrastructure (e.g. the Healthcare and Public Health sector) against physical and cyber threats such that these efforts reduce vulnerabilities, minimize consequences, and identify and disrupt threats. As part of sector-specific cybersecurity initiatives, CDRH seeks to create a collaborative information-sharing environment and decision framework that reduces risks to the public's health and allows rapid sharing of medical device vulnerabilities, threats, and mitigations within the hospital and healthcare ecosystem.

The H-ISAC, given its unique position as a non-profit organization, and its recognition by OHS, HHS, and the Healthcare and Public Health Sector Coordinating Council as the ISAC for the Healthcare and Public Health (HPH) Sector, is an essential partner in developing this collaborative information-sharing environment and decision framework. By leveraging the relationships that the H-ISAC has already developed with public and private sector stakeholders, it will be able to develop the specialized knowledge, processes and analytical capabilities needed to assess and drive cybersecurity vuln'erability mitigation in the HPH sector.

The Sensato-ISAO operates the Sensato Cybersecurity Tactical Operations Center (CTOC) as well as the Cybersecurity Tactical Training Center. The combination of these entities enables the Sensato-ISAO to utilize its threat collection capabilities, work with healthcare organizations, medical device manufacturers, incident response programs and other services to support Executive Order 13636 and the efforts, mission and responsibilities of H-ISAC as well as other entities who are critical to the analysis, evaluation, dissemination and response to cybersecurity intelligence and attacks against the healthcare sector.

Ill. Goals of Collaboration

1. Create an environment that fosters stakeholder collaboration and communication, and encourages the sharing of information about cybersecurity vulnerabilities that may affect the safety, effectiveness and security of the medical devices, and/or the integrity and security of the surrounding healthcare IT infrastructure. Ultimately, exploited vulnerabilities may have downstream public health and patient safety consequences.

2. Develop awareness of the Framework for Improving Critical Infrastructure Cybersecurity (developed by the National Institute for Standards and Technology, herein referred to as NIST, with collective input from other government agencies and the private sector), and enable HPH sector stakeholders to successfully adapt and operationalize the framework for their organizations and products.

3. Encourage stakeholders within the HPH Sector, to develop innovative strategies to assess and mitigate cybersecurity vulnerabilities that affect their products.

4. Build a foundation of trust within the HPH community (including but not limited to medical device manufacturers, end user facilities, providers and healthcare organizations) so that all healthcare technology and medical device stakeholders can directly benefit from the sharing of cybersecurity vulnerability and/or threat information identified within the HPH Sector, as well as intelligence feeds from other Critical Infrastructure Sectors that may secondarily affect healthcare and the public health. Gaining timely situational awareness of cybersecurity vulnerabilities that can have negative consequences for patient safety provides stakeholders with an opportunity to share solutions in advance of potential harm and possibly prevent economic or 'brand' damage. It would further enable owners and operators of critical infrastructure to proactively take appropriate measures to strengthen cybersecurity within the HPH sector with accuracy and agility.

IV. Substance of the Agreement

1. FDA intends to establish a mechanism by which information regarding cybersecurity vulnerabilities and threats can be shared with the H-ISAC and Sensato-ISAO. This MOU does not authorize, and FDA does not intend to, share any confidential commercial, trade secret, or personal privacy information with H-ISAC or Sensato-ISAO pursuant to this MOU.

2. H-ISAC and Sensato-ISAO intend to work with their members to establish a mechanism by which cybersecurity vulnerabilities relevant to medical devices are shared with each other and FDA, such that the existing agreements among H-ISAC and Sensato-ISAO members will not be infringed upon.

3. The parties intend to work together to establish mechanisms to ensure that essential medical device or healthcare cybersecurity vulnerability information can be shared with all stakeholders within the HPH Sector, including those who are not members of H-ISAC and Sensato-ISAO. This collaboration will help inform a common understanding of that risk threshold upon which exploit of a vulnerability might impact on patient safety and/or public health.

4. The base cybersecurity medical device policy and vendor assessment framework developed by the Sensato-ISAO's members will be freely available under open source license to the healthcare and public sector. Any and all contributions developed by the Sensato-ISAO membership will also be contributed to the common good and made available under an open source license.

5. Each Party will establish a principal point of contact to facilitate the actions carried out under this MOU.

V. General Provisions

1. This MOU represents the broad outline of the Parties' intention to collaborate in areas of mutual interest. All activities that may be undertaken by this MOU are subject to the availability of personnel, resources, and funds. This MOU does not affect or supersede any existing or future understandings or arrangements between the Parties and does not affect the ability of the Parties to enter into other understandings or arrangements related to this MOU. This MOU does not create binding,enforceable obligations against any Party. This MOU and all associated agreements will be subject to the applicable policies, rules, regulations, and statutes under which FDA the H-ISAC, and Sensato-ISAO operate.

2. Data Sharing Guidelines: The Parties may enter into separate Confidential Disclosure Agreements (CDAs) pertaining to certain data and information shared in accordance with this MOU. In accordance with applicable law and regulations, including, but not limited to, 21 U.S.C. 3310), 21 U.S.C. 360j(c), 18 U.S.C. 1905, 21 CFR 20.61 and 20.63, FDA will not share any confidential commercial information, trade secrets, or personal privacy information with H-ISAC or Sensato-ISAO pursuant to this MOU.

VI. Liaison Officers:

A. For the H-ISAC

Jon Crosson
Manager, Special Interest Group Services
226 North Nova Road, Suite 391
Ormond Beach, FL 32174
[email protected]

B. For the Sensato-ISAO

Kate Macaleer
SVP of Operations, Sensato
68 White Street, Suite 7-180
Red Bank, NJ 07701
844-736-7286 x 100
[email protected]

C. For the Food and Drug Administration

Suzanne B. Schwartz, M.D., M.B.A
Associate Director for Science and Strategic Partnerships
Center for Devices and Radiological Health
Food and Drug Administration
10903 New Hampshire Avenue
Building 66, Room 5434
Silver Spring, MD 20993 301-796-6937
[email protected]

or

Seth Carmody, Ph.D.
CDRH Cybersecurity Program Manager
Emergency Preparedness/Operations and Medical Countermeasures (EMCM) Program
Center for Devices and Radiological Health
Food and Drug Administration
10903 New Hampshire Avenue
Building 66, Room 4652
301-796-6944
[email protected]

Each Party may designate new liaisons at any time by notifying the other Party's administrative liaison in writing. If, at any time, an individual designated as a liaison under this agreement becomes unavailable to fulfill those functions, the Parties will name a new liaison within two (2) weeks and notify the other Party through the designated administrative liaison.

VII. Term, Termination. and Modification:

This agreement, when accepted by all participating Parties,will have an effective period of performance of five (5) years from the date of the latest signature and may be modified or terminated by mutual written consent by both Parties or may be terminated by either Party upon a thirty (30) day advance written notice to the other.

Approved and Accepted H-ISAC

/s/

Denise Anderson
President

September 2018

Approved and Accepted
Sensato-ISAO

/s/

John Gomez
Chief Executive Officer, Sensato

July 2018

Approved and Accepted
Food and Drug Administration
Center for Devices and Radiological Health

/s/

Jeffrey Shuren, M.D., J.D.
Director

September 2018